SGMT
Sagimet Biosciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.94
+0.18%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +19.4%
- EBIT
- +21.3%
- EPS
- +30.1%
- Free cash flow
- +23.8%
- Operating cash flow
- +23.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +22.7%
- EPS
- +2.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -12.0%
- EBIT
- -4.5%
- Net income
- -12.0%
- EPS
- -9.0%
- Free cash flow
- -7.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026